



Webinar

What lessons from Covid-19 for advancing antibiotic R&D?

Manica Balasegaram, Michelle Childs
29 April 2021

Q&A Session with the Participants

16:06:53

From Global Health Centre Research, Graduate Institute Geneva: Welcome to our webinar series at the Global Health Centre, The Graduate Institute of Geneva. Thank you for joining us. The recording and materials from the webinar will be made available at:

<https://www.knowledgeportalia.org/webinars>.

If you have any questions or comments, please type them in the chat box (don't forget to select "panelists and attendees"). You can also raise hand to pose your questions orally.

16:12:09

From Global Health Centre Research, Graduate Institute Geneva: The research paper being presented today is available at:

Learning from COVID-19 to Tackle Antibiotic Resistance

<https://gardp.org/news-resources/learning-covid19-antibiotic-resistance/>

16:13:56

From Karin Wiedenmayer: Are you aware of any publications regarding increased use of AB during Covid-19?

16:22:37

From Kirsten Myhr: Do you have any comments to the use of bacteriophages? A group at the Arctic Uni in Norway thinks these might replace narrow-spectrum antibiotics. And they are not patentable. Used in Eastern Europe in the past, I think.

16:28:49

From Donald Light: Could you please share your excellent slides? Is there a related paper too? Thanks.

16:32:46

From Pradeep Balachandran to Everyone : This is with reference to Dr. Manica's mention of a 'knowledge sharing network' - As part of antimicrobial profiling to assist

antimicrobial research, do we have globally shared repositories or databases that can facilitate the collection and characterization of these pathogens? This is to explore on possible options to minimize the R&D cost by promoting shared resources.

16:34:09

From Kathleen Doobay: Such a good question & point, Pradeep. This has come up in other communities around research, knowledge sharing & shifting from competitive culture to a more collaborative approach. Thank you / Merci @KathleenDoobay

16:39:05

From Derek Q de Stockalper: Do you see promising digitally-driven delivery models / business models reaching “last mile” or underserved patients?

16:40:01

From Pradeep Balachandran: Yes Kathleen , 'collaboration' is the key.

16:40:11

From Luciana Nemeth: Why is drug-resistant tuberculosis left aside the AMR discussion when it is responsible for almost 1/3 of deaths caused by drug-resistant pathogens?

16:41:17

From Kathleen Doobay: *collaborative. YES it is key, Pradeep! Important to acknowledge access differs worldwide & glad we continue to advocate for a global response.

16:46:19

From Janis Lazdins : North South partnerships in R&D are welcomed, however, as in the case for COVID-19 vaccines, many clinical trials were performed in LMICs however, as we know these countries still have not access to those, therefore fairness according to ethical principles must be enforced. Are you making this conditional in your agreements.

16:48:22

From Karin Wiedenmayer: Thank you Manica! I agree that there may be secondary bacterial infections in covid-19 which may increase use of AB plus obviously empirical tx without diagnostics. I would appreciate any hints to published research.

16:52:33

From Kathleen Doobay: Holistic approach including One Health framework is being used by the University of Calgary for research including innovative, cross collaborative approach with AMR & interventions with children. Enjoying today's webinar - gratitude for your ongoing work!

16:52:42

From Janis Lazdins: For both, your organization are perceived as the reference for R&D for the diseases you address, and most public funding goes through you, however, this is limited, limiting your portfolios, leaving many other innovative ideas particularly from the south not addressed, how can we make sure that donors see beyond your organizations?

16:53:02

From Kathleen Doobay: "Bridging with integrity"

16:55:03

From Marc Lemonnier: Is GARDP planning to expand its AMR scope outside of the current areas, eg drug-resistant TB or respiratory infections? How will GARDP adapt to changing priorities both in LMICs and globally?

17:01:34

From Kathleen Doobay: RE: including low & middle income countries, ethically, stewardship, etc. Such an important acknowledgement, Manica. Thank you all. Stay safe & well.

17:01:38

From Md Matin: Is GARDP planning to expand its AMR scope outside of the current areas through doctoral studies ?

17:05:27

From Pradeep Balachandran: Thank you very much Prof. Suerie, Prof. Michelle , Prof. Manica and all the delegates.

17:05:33

From Global Health Centre Research, Graduate Institute Geneva: Thank you for joining our webinar today. After the webinar, you will be directed to a survey page. We kindly ask you to take a few minutes to answer the questions in order to help us improve the quality of the webinar.

The recording and materials from the webinar will be made available at:
<https://www.knowledgeportalia.org/webinars>

You can:

- Subscribe to our mailing list: graduateinstitute.ch/globalhealth
- View all our upcoming events: graduateinstitute.ch/GHC-events
- Access research projects and publications: graduateinstitute.ch/globalhealth